⚡ Quick Overview / Key Takeaways for Investors
Is Molbio Diagnostics IPO a good buy? Sushil Finance assigns a 'SUBSCRIBE' recommendation to the Molbio Diagnostics IPO. The company features proprietary, globally-validated point-of-care (POC) PCR diagnostic technology ('Truenat'), robust revenue growth (41.6% YoY in FY26 to Rs 1,455.17 Cr), strong EBITDA margins (22-25%), and a solid return on net worth (14.55% in FY26). The Rs 200 Crore fresh issue is almost entirely dedicated to capital expenditure for R&D infrastructure and manufacturing capacity expansion.
1. Molbio Diagnostics IPO Overview
Molbio Diagnostics Limited has announced its Initial Public Offering (IPO) slated to open on August 10, 2026, and close on August 12, 2026. The company has fixed the price band at Rs 768 to Rs 807 per equity share with a face value of Rs 1/- per share. The total issue size stands at Rs 939.70 Crore, comprising a fresh issue of Rs 200.00 Crore and an Offer for Sale (OFS) of Rs 739.70 Crore.
The equity shares will be listed on both primary Indian stock exchanges-BSE and NSE. Book running lead managers for the issue include Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited, with KFin Technologies Ltd acting as the registrar.
2. Key IPO Details & Issue Breakdown
| Parameter |
Details |
| Price Band |
Rs. 768 to Rs. 807 per share |
| Issue Opens On |
August 10, 2026 |
| Issue Closes On |
August 12, 2026 |
| Lot Size |
18 Equity Shares & in multiples thereafter |
| Face Value |
Rs. 1/- per share |
| Total Issue Size |
Rs. 939.70 Crore (1,16,46,246 Equity Shares) |
| Listing Exchanges |
BSE & NSE |
| Registrar |
KFin Technologies Ltd. |
Offer Structure & Reservation Breakup
The offer comprises both Fresh Issue and Offer for Sale (OFS), allocated across investor categories as follows:
| Issuance Type |
Amount (in Rs. Cr.) |
| Fresh Issue |
Rs. 200.00 Cr |
| Offer for Sale (OFS) |
Rs. 739.70 Cr |
| Total Issue Size |
Rs. 939.70 Cr |
| Category Reservation |
% of Issue |
Amount in Cr. (at Upper Band) |
| QIB (Qualified Institutional Buyers) |
75% |
Rs. 704.78 Cr |
| HNI (Non-Institutional Investors) |
15% |
Rs. 140.96 Cr |
| Retail Individual Investors |
10% |
Rs. 93.97 Cr |
| TOTAL |
100% |
Rs. 939.70 Cr |
3. Company Overview: Molbio Diagnostics Limited
Molbio Diagnostics Limited is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid, and cost-effective healthcare technologies for diagnosing infectious and non-communicable diseases.
Its proprietary 'Truenat' platform is a novel POC polymerase chain reaction (PCR) system that operates on battery power in resource-limited settings. It delivers decentralized diagnostic results within an hour-representing a genuine technological breakthrough for molecular diagnostics, which have traditionally required centralized laboratory infrastructure.
Beyond molecular diagnostics, the company has expanded into radiology, digital pathology, and breast health screening devices through subsidiaries Prognosys and OptraScan, alongside a collaboration with UE Lifesciences, significantly broadening its addressable healthcare-technology footprint.
4. Objects of the Offer
The Offer comprises a Fresh Issue aggregating up to Rs. 200 Crore plus an Offer for Sale (OFS) of up to 91,66,000 equity shares by the Selling Shareholders (OFS proceeds do not accrue to the Company). The net proceeds from the Fresh Issue will be utilized toward the following targeted objects:
- Capital Expenditure for R&D Facility & Center of Excellence: Approximately Rs. 105.54 Crore is earmarked for setting up an R&D facility and Center of Excellence (to be operated by subsidiary Bigtec) along with connected office space.
- Plant & Machinery Purchase: Approximately Rs. 72.28 Crore will be used for purchasing plant, machinery, and equipment at the Goa Unit I, Goa Unit II, and Visakhapatnam manufacturing units.
- General Corporate Purposes: The balance amount (capped at 25% of gross proceeds) will be allocated for general corporate functions.
This is a clear R&D-and-capacity-led growth issue-nearly the entire quantified fresh-issue amount funds future product development and manufacturing capacity rather than debt repayment or promoter exit.
5. Key Business & Operational Highlights
- Circular Economy Leadership: One of India's leading players in the circular economy (lead and lead-alloy recycling).
- Risk Mitigation via Hedging: Structured hedging mechanism in place specifically to protect against commodity price risk.
- Strong Customer Base & Sourcing: Strong, diversified customer base backed by robust raw-material sourcing capabilities.
- Dual Exchange Listing: Dual exchange listing across domestic and international markets.
- Proven Profitability Track Record: Track record of consistent profitability across financial cycles.
7. Investment & Payment Chart (At Cut-off / Upper Price Band @ Rs 807)
Retail Category Application Price Chart
| Lots |
No. of Shares |
Minimum Bid Lot Amount (Rs.) |
| 1 Lot | 18 | Rs. 14,526 |
| 2 Lots | 36 | Rs. 29,052 |
| 3 Lots | 54 | Rs. 43,578 |
| 4 Lots | 72 | Rs. 58,104 |
| 5 Lots | 90 | Rs. 72,630 |
| 6 Lots | 108 | Rs. 87,156 |
| 7 Lots | 126 | Rs. 1,01,682 |
| 8 Lots | 144 | Rs. 1,16,208 |
| 9 Lots | 162 | Rs. 1,30,734 |
| 10 Lots | 180 | Rs. 1,45,260 |
| 11 Lots | 198 | Rs. 1,59,786 |
| 12 Lots | 216 | Rs. 1,74,312 |
| 13 Lots | 234 | Rs. 1,88,838 |
HNI Category Application Chart
| HNI Category |
No. of Shares |
Minimum Bid Lot Amount (Rs.) |
| Small HNI |
252 |
Rs. 2,03,364 |
| Big HNI |
1,242 |
Rs. 10,02,294 |
8. Indicative Molbio Diagnostics IPO Schedule / Timeline
| Tentative Events |
Indicative Dates |
| Issue Opens On |
August 10, 2026 |
| Issue Closes On |
August 12, 2026 |
| Finalisation of Basis of Allotment |
August 13, 2026 |
| Initiation of Refunds / Unblocking ASBA Funds |
August 14, 2026 |
| Credit of Equity Shares to Demat Accounts |
August 14, 2026 |
| Commencement of Trading on Exchanges (Listing Date) |
August 17, 2026 |
9. Our View / Research Recommendation
Molbio Diagnostics is a compelling Subscribe, anchored in a rare combination of proprietary, globally-validated technology and consistent, high-quality earnings growth.
Revenue grew from Rs. 1,027.94 crore in FY25 to Rs. 1,455.17 crore in FY26 (41.6% YoY, ~31.6% two-year CAGR), while PAT rose from Rs. 138.58 crore to Rs. 164.14 crore, sustaining EBITDA margins in the 22-25% range with visible operating leverage as scale increases.
RoNW has stayed consistently strong (12.6%-15.2% across three years), reflecting durable capital efficiency rather than a one-off spike. Furthermore, the fresh issue itself is almost entirely deployed toward R&D infrastructure and manufacturing capacity-a genuine growth-funding issue rather than a leverage-reduction or promoter-exit vehicle.
10. Frequently Asked Questions (FAQs)
Q1: What is the price band for Molbio Diagnostics IPO?
The price band for Molbio Diagnostics IPO is set between Rs. 768 and Rs. 807 per equity share with a face value of Rs. 1 per share.
Q2: What is the minimum lot size and investment for retail investors?
The minimum bid lot size is 18 equity shares, requiring a minimum investment of Rs. 14,526 at the upper price band of Rs. 807 per share.
Q3: What makes Molbio Diagnostics' Truenat platform unique?
Truenat is a proprietary point-of-care PCR system that operates on battery power in resource-limited settings, delivering decentralized diagnostic results within an hour without requiring centralized lab infrastructure.
Q4: How has Molbio Diagnostics performed financially over the past 3 years?
Total income increased from Rs. 840.66 Cr in FY24 to Rs. 1,027.94 Cr in FY25 and Rs. 1,455.17 Cr in FY26. PAT grew from Rs. 83.54 Cr in FY24 to Rs. 164.14 Cr in FY26 with robust RONW between 12.62% and 15.23%.
Q5: Who are the book running lead managers for this IPO?
The lead managers are Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited.
DISCLAIMER
The content provided in this blog is for informational and educational purposes only and should not be construed as investment, legal, or tax advice. While Sushil Finance makes reasonable efforts to ensure accuracy and reliability of the information, we do not guarantee its completeness or timeliness. Readers are advised to consult with their financial advisor before making any investment decisions. Sushil Finance shall not be held responsible for any direct or indirect loss arising from use of this content. Investments in securities are subject to market risks. Read all scheme-related documents carefully before investing.
